Since 2010, ScreenCell has produced easy-to-use devices allowing the detection of circulating tumor cells (CTCs) fixed or live (unaltered) quickly and efficiently.
Circulating tumor cells (CTCs) are emerging as a major asset in the service of oncology. Their ability to provide real-time information on cancer progression opens new avenues in aiding early diagnosis and personalizing treatments.
Simple, easy-to-use technology
A rapid isolation process for Circulating Tumor Cells (CTCs)
A single-use device
An isolation system based on the size of cancer cells
A high recovery rate
An economical solution
Monitoring the progression of cancer is a complex mission. Using liquid biopsy with ScreenCell during your next tests will ensure you have more information about the progress of the cancer.
Furthermore, our technology is compatible with other methods such as circulating DNA analysis and exosome analysis.
ScreenCell’s mission is guided by a deep conviction: to actively contribute to improving the lives of cancer patients by constantly pushing the boundaries of oncology research.
We are committed to providing innovative solutions and cutting-edge technologies for early detection of cancer cells and increased understanding of the disease.
Our passionate team of researchers, scientists and liquid biopsy experts are driven to advance personalized medicine to provide better treatments and a better quality of life for all patients.
With a human-centered approach and attentive listening to the needs of researchers and clinicians, we work hand in hand with the medical community to turn every discovery into an opportunity to save lives.
Discover the scientific publications in which ScreenCell technology has been used.
Circulating tumor cells (CTCs) represent a rare and heterogeneous population of cancer cells thatare detached from the tumor site and entered blood or lymphatic circulation. Once disseminatedin distant tissues, CTCs could remain dormant or create a tumor mass causing serious danger forpatients. Many technologies exist to isolate CTCs from patients’
We are thrilled to announce the publication of our latest scientific article titled “Fast and efficient isolation of murine circulating tumor cells using screencell technology for pre-clinical analyzes”.
We would like to extend our heartfelt thanks to the authors of this article: Fei Ye, Janine Wechsler, Amira Bouzidi, Georges Uzan & Sina Naserian for their outstanding work and invaluable contribution to scientific and medical research.
To learn more and read the full article, click the button below.
We are proud to announce that Sina NASERIAN, our Technical Director, has successfully obtained the “Habilitation à Diriger des Recherches” (HDR) from the University of Paris Est on December 7, 2023.
This recognition is a testament to his exceptional dedication and remarkable expertise. We look forward to witnessing the significant achievements that will result from this success.
Congratulations to Sina for this significant accomplishment!
Our team was present from November 1 to 4 at the 22nd PACC in Algiers, alongside our partner Genethical.
During this event, we were able to discuss and present ScreenCell’s different objectives in France and Algeria through various subjects such as our current clinical trial on breast cancer and our other upcoming projects.
Our collaborators also took part in the Scientific Day on Breast Cancer and Precision Medicine, the October 31, 2023, organized at the INSP (Institut National de Santé Publique) where we were invited by Pr. A. BOUAMRA.
On July 14 and 15, ScreenCell was present at the Master Class on Digestive Cancers organized by the Algerian Society for Training and Research in Oncology in Algiers.
During this MasterClass, we presented the interest of circulating tumor cells (CTC) for clinical oncology, using ScreenCell technology.
